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Inhibitors of the renal outer medullary potassium channel: a patent review. 
Abstract 
Introduction: Hypertension represents a substantial cardiovascular risk factor. Among anti-
hypertensive drugs, diuretics play an important role. Nevertheless, they present adverse effects like 
hypokalemia or hyperkalemia. In this panorama, inhibitors of the renal outer medullary potassium 
(ROMK) channels are emerging because they are predicted to give a diuretic/natriuretic activity 
higher than that provided by loop diuretics, without hypokaliemic and hyperkaliemic side effects.  
Areas covered: This article reviews the current literature, including all the patents published in the 
field of inhibitors of the ROMK channels for the treatment of hypertension, heart failure and 
correlated diseases. The patent examination has been carried out using electronic databases 
Espacenet. 
Expert opinion: Although anti-hypertensive drugs armamentarium enumerates a plethora of 
therapeutic classes, including diuretics, the novel class of ROMK inhibitors may find a place in this 
crowded market, because of the diuretic/natriuretic effects, devoid of worrying influence on 
potassium balance. The patent examination highlights, as a strength, the individuation of a 
successful template: almost all the compounds show noteworthy potency. However, only few 
selected compounds underwent an in vivo investigation of diuretic and anti-hypertensive activities, 
and no data on hERG channel are given in these patents. 
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Article highlights 
 Hypertension is a common chronic disease characterized by elevated systemic arterial blood 
pressure. It represents a risk factor for several cardiovascular accidents; hence, the therapy 
for hypertension is of fundamental importance. 
 Heart failure is another widespread pathologic condition which leads to edematous states 
often treated with diuretic drugs. 
 Diuretics agents have a key role, but could present adverse effects, such as for example, 
hypokalemia for loop and thiazide diuretics and hyperkalemia for amiloride.  
 A new class of diuretics, inhibitors of the renal outer medullary potassium (ROMK) 
channels, is predicted to give a diuretic/natriuretic activity higher than that provided by loop 
diuretics, thanks to ROMK channels in TALHL and CDD. 
 About twenty patent and 1700 compounds by Merck Sharpe & Dome have been examined: 
IC50 values determined in in vitro electrophysiological, thallium flux and 86Rb+ efflux assays 
are reported. Few selected compounds underwent deeper pharmacological characterization 
in vivo on rat diuresis and recording of blood pressure on spontaneously hypertensive rats. 
 On the basis of these preliminary data, some selected compounds are promising prototypes 
of a newest class of diuretic agents useful for hypertension and heart failure. 
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List of abbreviations: 
ROMK = renal outer medullary potassium  
TALHL = thick ascending limb of Henle’s loop  
CCD  = cortical collecting duct 
CT  = collecting tubule  
ENaC = epithelial sodium channel 
PKA = protein kinase A  
PIP2 = phosphatidylinositol 4,5-biphosphate  
CFTR = cystic fibrosis transmembrane conductance regulator  
HTS = high-throughput screening  
CHO = Chinese hamster ovary 
HEK = human embryonic kidney 
SAR = Structure Activity Relationships  
MSD = Merck Sharp & Dome 
SHR = spontaneously hypertensive rats  
BK = Large-conductance Ca2+-activated potassium channels  
EP  = electrophysiology  
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1. Introduction  
The renal outer medullary potassium (ROMK or Kir 1.1) channel belongs to the family of inwardly 
rectifying potassium channels and plays an important role in K+ recycling in the thick ascending 
limb of Henle’s loop (TALHL) across the luminal membrane and in K+ secretion in the collecting 
tubule (CT) and especially in the cortical collecting duct (CCD) [1-3]. At the TALHL level, the 
ROMK channel mediates the K+ efflux required by the Na+/K+/2Cl- co-transporter for NaCl 
transport, important for the urinary concentrating mechanism, and contributes to the TALHL 
transepithelial current flow and membrane potential necessary for paracellular Na+ and Ca2+ 
reabsorption (Figure 1) . Therefore, the pharmacological inhibition of the ROMK-mediated 
potassium flow into the lumen is coupled with an indirect inhibition of  the Na+/K+/2Cl- co-
transporter, without the potassium leak, typical of the direct inhibitors of this co-transporter (i.e. 
loop diuretics). Instead, on the principal cells of the CCD, the ROMK channel represents the 
fulcrum of the K+ secretion pathway, coupled with the Na+ uptake through the amiloride-sensitive-
Na+ channels (or the epithelial sodium channel, ENaC), and is essential for K+ homeostasis [4] 
(Figure 1). Consistently, the pharmacological inhibition of the ROMK channels impedes the 
K+/Na+ exchange in the CDD. Even if the ROMK channels are the most important pathway for the 
K+ secretion into the lumen, ROMK inhibition is not associated with the K+ retention and 
consequent hyperkalemia (typical of ENaC inhibition), because of the compensatory activation of 
the large-conductance Ca++-activated potassium channels (BK) (Figure 1) [5].  It is therefore 
evident that factors influencing the activity of the ROMK channel have a crucial role on K+ 
secretion and renal concentrating mechanisms, and can deeply influence diuresis and blood pressure 
regulation.  
Many endogenous intracellular factors regulate the ROMK channel: protein kinase A (PKA), 
phosphatidylinositol 4,5-biphosphate (PIP2), ATP and pH. PKA-mediated phosphorylation on three 
separate sites regulates the channel opening process and is necessary for full channel function [6]; 
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PIP2 is an essential Kir channel cofactor, required to maintain the open state of all inward-rectifying 
potassium channels, and the ROMK channel tightly interacts with PIP2 [7]. Moreover PKC-induced 
PIP2 hydrolysis inhibits ROMK channel activity in Xenopus oocytes suggesting an explanation for 
PKC modulation of the ROMK channel in the collecting duct [8]. Differently from a classical ATP-
sensitive potassium channel, the ROMK channel is inhibited by physiological concentration of 
cytosolic ATP so long as it is expressed with the cystic fibrosis transmembrane conductance 
regulator (CFTR) [9]. Finally, intracellular pH influences ROMK channel activity, because a 
cytosolic acidification inhibits the ROMK channel and induces a long-live closed state [10]. ROMK 
channels are localized in TALHL, CT and CCD, (Figure 1) which are the sites of action of three 
different classes of diuretics respectively: a) Na+/K+/2Cl- co-transporter, responsible for ~ 30% of 
salt reabsorption, represents the pharmacological target of furosemide (the prototypical loop 
diuretic); b) the Na+ /Cl- co-transporter, responsible for ~ 7% of salt reabsorption, is the 
pharmacological target of thiazide diuretics; c) the amiloride-sensitive epithelial Na+ channels 
(ENaC), i.e. the pharmacological target of amiloride and triamterene. Due to the tight coupling 
between Na+ reabsorption and K+ secretion in the CCD, loop and thiazide diuretics are associated 
with hypokalemia, while amiloride induces hyperkalemia. On the contrary, the new class of diuretic 
drugs, able to inhibit selectively the ROMK channels, would be predicted to give a 
diuretic/natriuretic activity higher than that provided by loop diuretics (thanks to the ROMK 
channels in the TALHL), with reduced risk of hypokalemia typical of loop diuretics and thiazides 
[11], thanks to ROMK in CCD. Moreover, the observation that type II Bartter’s syndrome, a rare 
autosomal recessive salt-wasting nephropathy characterized by polyuria, hypokalemia, metabolic 
alkalosis and hypotesion, caused by inactivating mutations in the ROMK channels [12], leads to 
reduced blood pressure values [13], reinforces the belief that the ROMK channels may be new 
targets for a new class of diuretic agents employable in hypertension and edematous states such as 
heart failure.  
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2. ROMK inhibitors 
The first discovered ROMK inhibitor was a bee venom peptide, tertiapin, which was able to inhibit 
rat channel, but it was 100-fold less potent on human isoform [14,15]. In 2009, Lewis and 
colleagues, at the Vanderbilt University, through high throughput screening, discovered a small-
molecule that was an inhibitor of the ROMK channel: VU590 (7,13-bis(4-nitrobenzyl)-1,4,10-
trioxa-7,13-diazacyclopentadecane) [16]. Subsequently, the synthetic exploration of VU590, led to 
the identification of a structurally related small-molecule, VU591 (2,2I-oxybis(methylene)bis(5-
nitro-1H-benzo-[d]imidazole) [17] (Figure 2). VU590 and VU591 inhibit ROMK interacting with 
its intracellular pore with IC50 values of 0.29 and 0.24 µM, respectively. As regards the other 
inwardly rectifying channels expressed in the kidney (see Figure 1), VU590 has no activity on 
Kir2.1 and Kir4.1, but inhibits Kir7.1; while, VU591 shows a higher selectivity for Kir1.1 over 
other Kir channels. Moreover, VU591 inhibits potassium transport (without effetcs on net sodium 
transport) in the experimental model of isolated-perfused rat collecting distal tubules, suggesting an 
encouraging basis for ROMK inhibition in further in vivo experiments [16,17]. Independently from 
the studies of the Vanderbilt's group, Merck researchers carried out an high-throughput screening 
(HTS) on about 1.5 M molecules and, among them, the 4-nitrophenethyl-piperazine (Compound 1, 
Figure 3) was early, but erroneously, indicated as a lead ROMK inhibitor and submitted to 
extensive studies for identifying its possible activity on other relevant potassium channels, such as 
Kir2.1 (the inhibition of Kir2.1 channels expressed in heart ventricle is recognized in long QT 
syndrome) and hERG (hERG inhibition is considered the main undesidered mechanism of QT 
prolonging cardiotoxic drugs, such as cisapride [18]. Unexpectedly, when Compound 1 was 
subjected to repurification by HPLC, the ROMK inhibitory activity was lost. Through a careful 
examination of the LC-MS features it was discovered that the activity was not due to Compound 1, 
but to a minor impurity that was present before the repurification: 1,4-bis(4-
nitrophenethyl)piperazine (Compound 2). Compound 2 displayed good ROMK inhibitory activity 
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(IC50=0.052 µM) and excellent selectivity over the Kir2.1 and Kir2.3 channels (IC50>100 µM). 
Unfortunately, it showed  high potency on the hERG channel (IC50=0.005µM) [19,20] (Figure 3). 
Starting from this lead compound, the Merck researchers' strategy focused on the identification of 
bioisosteric replacements of the nitro groups. Among them, benzonitriles, 5-benzo(2,1,3-
oxadiazole) and 4-phthalide groups maintained an appreciable ROMK block, but only the 4-
phthalide moiety (Compound 3) led to a very encouraging result, reducing the potency on hERG by 
about 20-fold (ROMK IC50= 0.089 µM, hERG IC50= 0.15 µM) (Figure 4). Other Structure Activity 
Relationships (SAR) showed that even small changes in the distance between the nitro groups (both 
in shortening and in lengthening), as well as methyl substitution in the core skeleton, resulted in 
loss of potency [19]. In a second generation of ROMK inhibitors (developed by Merck), researchers 
explored analogues of compound 2 in which both the nitrophenyl groups were replaced with bis-4-
cyanophenyl, bis-5-benzo (2,1,3-oxadiazole) or bis-4-phthalide. The latter showed an appreciable 
ROMK inhibitory potency, being about 20-fold selective over the hERG channel (ROMK IC50= 
0.089 µM, hERG IC50= 1.9 µM) (Compound 4, Figure 4). The hybridization of these three 
pharmacophores led to a series in which compound 5 represented the most potent ROMK inhibitor 
(ROMK IC50= 0.30 µM, hERG IC50= 0.43 µM) (Figure 4). Further investigations on compound 5 
demonstrated that halides substituents (in ortho position to the nitrile group) gave derivatives 
almost equivalent to compound 3; while, an increase in the size of the substituents determined a 
decrease in ROMK inhibitory potency. Interestingly, among them, some analogues markedly 
improved the pharmacokinetic properties [19]. As a further attempt to replace the 4-nitrophenyl 
group with bioisosteric moieties, Merck researchers synthesized a series of new di-substituted 
piperazines characterized by a 4-phthalidyl ethyl group and a 4-(1H-tetrazol-1-yl)phenyl methyl 
amide, as N-substituents [21]. Different patterns of substitutions on the tetrazole phenyl ring or on 
the phthalide ring were exploited; nevertheless, the simpler unsubstituted 5-(2-(4-(2-(4-(1H-
tetrazol-1yl)phenyl)acetyl)-piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one (Compound 6, Figure 4) 
showed the most appreciable profile, because it maintained Kir1.1 inhibitory activity, was selective 
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for Kir1.1 over Kir2.1, Kir2.3, Kir4.1 and Kir7.1 and had a weakest inhibitory activity on hERG. This 
molecule, submitted to further pharmacological evaluation in vivo, showed good oral bio-
availability and a dose-dependent increase in urinary flow and urinary sodium excretion after short-
term oral administration to rats and dogs. This effect was comparable to that of hydrochlorotiazide 
(HCT) but, unlike HTC, compound 6 was not associated with the typical hypokalemia induced by 
the use of loop and thiazidic diuretics [22].  
 
3. Patenting activity of ROMK inhibitors 
Starting from the second decade of this century, Merck Sharp & Dome (MSD) company and some 
researchers of the MSD network, started an intense activity of patenting which led in a few years to 
about twenty patents. They cover approximately 1700 examples of molecules, mainly based on a 
common template constituted by “pharmacophore-linker-core-linker-pharmacophore”. In order to 
demonstrate ROMK inhibitory activity, some different tests were carried out and in particular 86Rb+ 
efflux assay that measures the ability of ROMK to permeate 86Rb+ in response to the test 
compounds. Rb+ is a K+ mimetic cation which flows across the cell membranes through all the K+ 
channels. Normally, CHO-DHFR cells, stably expressing hROMK (Kir1.1) and pre-loaded with 
86Rb+, show a time-dependent efflux of the isotope, after incubation with a Rb+-free buffer. The rate 
of this efflux depends on the number of functional K+ channels and is prevented in a concentration-
dependent manner by the presence of a channel inhibitor, allowing to calculate the IC50 of inhibitory 
activity for each test compound. Another ROMK functional assay reported in these patents is that 
based on the ability of Tl+ (another K+ mimetic cation) to permeate through open ROMK channels 
and determine an increase of fluorescence in a Tl+-sensitive dye pre-loaded into the cells. According 
to this assay, performed through FluxOR Kit (Invitrogen), HEK293 cells stably expressing hROMK 
(hKir1.1), pre-loaded with the dye and then exposed to a thallium-containing medium, show a time-
dependent increase in fluorescence which in proportional to the number of functional channels. The 
incubation of cells with a channel inhibitor leads to concentration-dependent attenuation of 
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fluorescence and allows to determine accurately the IC50 values of inhibition due to the incubation 
of test compounds. Some authors highlight important limitations of Tl+ flux-based high-throughput 
screen: the optical properties of the fluorescent probe could be affected by tested compounds. 
Besides, small-molecules could alter endogenous pathways of Tl+ flux in HEK293 cells, giving a 
false-positive hits. Finally, Tl+ has a low solubility in chloride-containing buffers and this implies 
the use of low concentrations of Tl+ or of non-physiological buffers . However they conclude that 
the limitations of this useful assay could be exceeded by voltage clamp electrophysiology, which is 
considered the "gold-standard" method for ion channel pharmacology [23]. 
The third in vitro assay, employed to give IC50 values for inhibitors, consisted in the measurements 
of the electrical current generated by the permeation of potassium through the channel. For these 
electrophysiological experiments, three different platforms: Ion Works, QPatch or manual patch 
clamp were used. To define a test compound as a ROMK inhibitor, it must show potencies of at 
least 1 µM or lower in one or more of the three above assays [24]. 
In vivo assays, concerning rat diuresis and the recording of systolic blood pressure on spontaneously 
hypertensive rats (SHR) after test compound administration, are reported in patents exhamined, but 
only for the fewest selected agents. 
Diuretic efficacy was carried out on Sprague-Dawley rats which received a per os dosage of the 
selected compounds. Then animals urine was collected for four hours by the use of a metabolic 
cage. For studies on hypertension, SHR were implanted with a telemetric device able to record 
blood pressure for 30 seconds every 10 minutes. Hydrochlorothiazide (25mg/Kg/day, per os) was 
included as reference diuretic drug. The selected compounds were administered in a sigle oral 
gavage each day for a typical duration of three to fourteen days [25]. 
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3.1 MSD Corp. WO2012058134 A1 
Patent application publication number WO2012/058134 A1, describes ROMK inhibitors having the 
generic formula reported in Figure 5A wherein A and B are mono and/or bicyclic aromatic groups; 
R2 is –H, -C1-6  alkyl, -C3-6 cycloalkyl, -CF3, -CH2OH, or –CO2R, or R2 can be joined up with R1 or 
R10a to form a ring; R3 is –H, -C1-6 alkyl, -C3-6 cycloalkyl, -OH, -F, -OC1-3 alkyl, or –CH2OH, or R3 
can be joined up with R10b to form a ring. The authors claim to have performed the three in vitro 
assays on cells and the two in vivo assays on rats (described in the previous paragraph) and they 
highlight the ROMK electrophysiological assay IC50 (µM) for a selection of compounds showing 
levels of potency lower than 1 µM, (as required to be defined as a ROMK inhibitor). Examples of 
these selected compounds are shown in Figure 5B and 5C [25]. 
3.2 MSD Corp. WO2013039802 A1 
In this second patent MSD describes several compounds having, as a shared structure, the formula 
reported in Figure 6A characterized by a piperidine core. Examples of tested compounds were 
tested in the electrophysiology assay and found to have a therapeutic level of potency. In this patent, 
the in vivo method of rat diuresis was also described, but examples of promising compounds are 
highlighted through 86Rb+ efflux assay which allowed to identify new molecules showing values of 
IC50 ≤ 0.2 µM (such as the compound shown in Figure 6B) or through Thallium flux assay in 
which different compounds, (example 6C) showed an IC50 ≤ 0.1 µM [26]. 
3.3 MSD Corp. WO2013062900 A1 and WO2013062892 A1 
The third patent of the MSD series shows compounds deriving from a general structure 
characterized by an oxo-piperazinic core, as reported in Figure 7A. Derivatives of this general 
formula underwent Thallium flux assay. Different examples showed appreciable levels of potency 
(IC50 values lower than 0.25 µM): in particular compounds reported in Figure 7B and in Figure 7C 
were the most potent of this series [27]. Starting from the same general structure 7A, but with 
different substituents, a further patent reported another series of potential ROMK inhibitors tested 
through 86Rb+ efflux assay or Thallium flux assay. Among these examples, two structurally 
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correlated molecules showed the best IC50 values: the compound reported in Figure 7D (that is a 
mixture of two enantiomers) and the compound shown in Figure7E (that is composed of two 
diastereomers) [28]. 
3.4 MSD Corp. WO2012058116 
This patent describes ROMK inhibitors, having the generic formula shown in Figure 8A, 
characterized by a piperazine core, wherein R5 and R6 are independently -H, -C1-6 alkyl or -
C(O)OC1-3alkyl; and X, X1, Y and Y1 are independently -H or -C1-6 alkyl; or Y1 can be joined up 
with Z2 to form a fused ring system. In the series of examples described in this patent, two 
derivatives exhibited remarkable levels of potency determined respectively by 86Rb+ efflux assay 
(as in the case of the two diastereomers reported in Figure 8B) or through Thallium flux assay (for 
compounds in Figure 8C) [29]. 
3.5 MSD Corp. WO2014015495 A1 
Patent application publication number WO2014/015495 A1 (having an update in the number of 
examples in the patent application publication number US2014/0031349 A1), describes a series of 
compounds having the generic formula shown in Figure 9A, characterized by a aza-spirocyclic 
core, which have remarkable levels of potency determined by electrophysiological assay 
(compound described by Figure 9B) or Thallium flux assay (compound in Figure 9C). Four 
selected compounds, described in this patent, were tested also in the in vivo measurement of systolic 
pressure on SHR: in this assay, compounds administered per os at doses in the range of 0.3 to 10 
mg/Kg promoted a typical reduction in the daily mean systolic blood pressure, ranging from 6 to 24 
mmHg. An example of the compounds tested in vivo is reported in Figure 9D [30,31]. 
3.6 MSD Corp. WO2010129379 and US20140142115. 
Patent application publication number WO2010/129379 (having an update in the patent application 
publication number US2014/0142115 A1), focuses on a piperazine core and describes compounds 
having the general formula represented in Figure 10A. Although several described derivatives 
showed appreciable level of ROMK inhibitory potency in the electrophysiology assay, as for 
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example compound in Figure 10B, there is a compound (reported in Figure 10C) which exhibited a 
remarkable profile in most of the biological assays, such as thallium flux, electrophysiology, rat 
diuresis evaluation and recording of systolic blood pressure on SHR. In particular, compound 10C, 
which has a symmetrical structure, is a 5,5'-{piperazine-1,4-diylbis[(1R)-1-hydroxyethane-2,1-
diyl]}bis(4-methyl-2-benzofuran-1 (3H)-one) and besides exhibiting very low levels of IC50, is one 
of the selected derivatives able to induce a 2-9 fold increase in urine volume with respect to the 
vehicle. 10C belongs to a restricted group of compounds able to determine a reduction of systolic 
pressure levels from 8 mmHg to 32 mmHg, when administered per os at doses ranging from 3 to 10 
mg/Kg. [32,33]. 
3.7 MSD Corp. WO2014085210 A1 
In this patent, examples with a piperidine-based core are illustrated and a general formula was 
identified in Figure 11A. ROMK inhibitors with good levels of potency in two in vitro assays, 
thallium flux and electrophysiology, were individuated: the compound shown in Figure 11B is a 
good example. However, also other compounds were highlighted because of an appreciable IC50 
value in the Thallium flux assay and an anti-hypertensive activity in the in vivo assay based on the 
measurement of systolic pressure on SHR. In fact, according to the results shown in this patent, 
compounds like 11C, administered per os at doses in the range 0.3-10 mg/Kg, caused a reduction in 
daily mean systolic blood pressure ranging from 6 mmHg to 24 mmHg [34]. 
3.8 MSD Corp. WO2013028474 A1 and WO2014099633 A2 
Patent WO2013/028474 A1 describes a series of ROMK inhibitors having a general formula 
characterized by a heterobicycle (one of the two fused rings is pirazine) and shown in Figure 12A. 
Some examples, like the compound reported in Figure 12B, are highlighted because of their low 
IC50 values both in thallium flux and in electrophysiology assays. Instead, other compounds, as for 
example 12C, are described as anti-hypertensive because of their ability to low systolic pressure in 
SHR, in a range of 7-21 mmHg, after oral administration of doses from 3mg/Kg to 10 mg/Kg [35]. 
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A very similar general structure (Figure 12D) was described in patent WO2014/099633 A2, in 
which compound illustrated in Figure 12E results the best example as concerns IC50 values both in 
thallium flux and in electrophysiology assays [36]. 
3.9 MSD Corp. WO2014126944 A2 and US20140336177 A1 
Structural analogies with the general formulas previously described in patents WO2013/028474 A1 
and WO2014/099633 A2 are detectable in two other subsequent patents: WO214/126944 A2 with 
general formula reported in Figure 13 A, and US2014/0336177 with the general formula shown in 
Figure 13D. From in vitro experiments, the example represented in Figure 13B emerges as a 
ROMK inhibitor with appreciable values of IC50 both in the Thallium flux and the 
electrophysiology assays. Compound in Figure 13C and its analogues were selected for the in vivo 
recording of systolic blood pressure on SHR after oral administration in doses from 3mg/Kg to 10 
mg/Kg: in this assay, the selected compounds were able to evoke a lowering of the systolic blood 
pressure of a 9,5-21 mmHg. In patent US2014/0336177, among several compounds deriving from 
the general formula 13D, compounds 13E showed an appreciable IC50 value in the Thallium flux 
assay and a remarkable IC50 value in the electrophysiological one. It was also selected for a 
deepening in vivo study on SHR. Like other selected compounds, it promoted a lowering of the 
systolic blood pressure of 7-25 mmHg after oral administration in doses from 3mg/Kg to 10 mg/Kg 
[37,38].  
3.10 MSD Corp. US20140309213 A1, US20140288042 A1 and US20140275020. 
Patents US2014/0309213 A1 and US2014/0288042 A1 describe a series of ROMK inhibitors 
having the same general formula (Figure 14A) but, despite this similarity, substituents and the core 
are characterized by different chemical moiety: for example, in the case of patent US2014/0309213 
A1 the core could be a diazatricyclo, a diazabicyclo heptan, a diazabicyclo octane, a diaza-spiro 
octane, a oxa-diazabicyclo nonane or a piperazine. While, in the case of patent US2014/0288042 
A1, we can find a diazaspiro nonane, a diazaspiro decane, a diazaspiro undecane, a diazabicyclo 
heptan, a pyrrolo-pyrrolo and a pyrrolo-piperidine. In both patents, ROMK inhibitors were tested 
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through thallium flux and electrophysiology assays and some compounds like those depicted in 
Figure 14B (described in patent US2014/0309213 A1) or the example represented in Figure 14C 
(highlighted in patent US2014/0288042 A1) showed an appreciable value of IC50 in both the in vitro 
assays [39,40]. Patent US2014/0275020 presents ROMK inhibitors having the general formula 
(Figure 14D) very similar to that represented in Figure 14A, with different cores mainly 
represented by amino-pyrrolidin, amino-cyclo-pyrrolidin, amino-methyl pyrrolidin, amino-methyl-
piperidine and azetidin moieties. Again compounds like, for example, those illustrated in Figure 
14E,  were tested through the two assays of Thallium flux and electrophysiology, and showed 
profiles compatible with a ROMK inhibitor [41]. 
3.11 MSD Corp. WO2014150132 A1 and WO2015017305 A1 
These recent patents on ROMK inhibitors share a spirocyclic moiety at the core position. In 
particular in patent WO2014/150132 A1 we can find the general structure represented in Figure 
15A and characterized by a diaza-spirodecanone core and  by a tetrazole and an oxo-dihydrofuran 
as lateral pharmacophores. Two of the most representative derivatives described in this patent 
(Figure 15B and C) showed remarkable values of IC50 obtained through thallium flux assay and 
anti-hypertensive activity on SHR when administered per os at doses in the range of 0.1-10 mg/Kg 
resulting in typical reductions in daily mean systolic blood pressure ranging from 5 to 33 mmHg. 
On the other hand, in patent WO2015/017305 A1, the spirocyclic moiety of the general formula 
shown in Figure 15D was mainly represented by diaza-spirodecano or diaza-spiro-undecan pirazine 
as in two of the most potent ROMK inhibitors highlighted in Figure 15E and F evaluated through 
the thallium flux assay [42,43]. 
 
4. Conclusions 
The last five years represented a period of continuous flourishing in the field of synthesis and 
pharmacological characterization of ROMK inhibitors: about twenty patents covering 
approximately 1700 examples of molecules were presented by MSD. For all these molecules, at 
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least data on in vitro determination of IC50 as ROMK inhibitors were shown and often the tested 
compounds showed IC50 values lower than 1 µM in one or more of the three in vitro assays 
described (the necessary condition for defining a molecule as a ROMK inhibitor). Selected 
compounds of some patents (as for example compound represented in Figure 10C)  were reported 
to display diuretic activity on a Sprague-Dawley rat diuresis model: in fact they were able to induce 
up to 9-fold increase in urine volume after an oral dose of 1-3 mg/Kg. Other compounds (as for 
example  molecules reported in Figure 9D, 10C, 11C, 12C, 13C, 13E, 15B and 15C) were reported 
to lower blood pressure (about 6-24 mmHg), after oral administration of doses in a range 0.1-
10mg/Kg to SHR implanted with a telemetric device that allowed a continuous recording of systolic 
blood pressure [30-38; 42,43]. However although the pharmacokinetic in vivo or the activity on 
other types of potassium channels, were often unrevealed, clinical data should certainly be obtained 
in the future and the support of computational modeling studies could be useful to define ligand-
ROMK interactions [44] , we can assert that this impressive development of novel selective ROMK 
inhibitors constitutes a promising basis for the birth of a newest class of diuretics. 
 
5. Expert opinion 
Presently, the area of marketed cardiovascular drugs is widely covered and especially anti-
hypertensive drugs are well represented by several classes with a variety of mechanisms of action 
which allow to satisfactorily treat most patients with suitable therapies. Of course, every therapy 
presents weaknesses and adverse effects; this makes extremely interesting and still compelling 
every improvement of the pharmacological armamentarium in this field. Hence, although it seems 
very difficult to find a place for a new class of drugs in this area, this challenge is even more 
attractive and timely, and the work is harder than in other pharmacological fields. In the widest 
number of cardiovascular drugs, endowed with very heterogeneous mechanisms of action, diuretics 
are widely used, in monotherapy or in association with other drugs, in the pharmacological 
treatment of hypertension and heart failure (together with other non-cardiovascular uses). In 
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particular, treatment with diuretics, such as thiazide ones, often represents an effective first-line 
approach to hypertension [45]. Indeed, thiazide diuretics are equivalent to other classes of 
antihypertensive agents in reducing cardiovascular events in hypertensive patients and are 
considered even superior than beta-blockers and angiotensin-converting enzyme inhibitors in 
reducing stroke incidence. Loop diuretics, less used in hypertension, are more effective in 
improving the outcomes of heart failure. Even ENaC blockers, such as amiloride, are used for 
hypertension, often associated with other drugs. However, although the above currently used 
diuretic drugs are endowed with an overall positive risk-benefit balance, they are not devoid of 
worrying side effects. In fact, they cause clear class-related alteration of potassium homeostasis: 
loop and thiazide diuretics are associated with hypokalemia, while inhibitors of ENaC induce 
hyperkalemia. The novel class of ROMK inhibitors, described in the patents examined, was 
designed to act as diuretics. This new class of diuretic drugs is expected to give a diuretic/natriuretic 
activity higher than that provided by loop diuretics, with limited effects on potassium homeostasis 
[11]. Therefore, ROMK inhibitors can actually represent an improvement worth pursuing. In my 
opinion, this is the premise for believing that they may constitute, in the next few years, a new class 
of diuretics employable, alone or in combination with other drugs, in hypertension and edematous 
states such as heart failure. The patent examination highlights as a strength, the individuation of a 
successful chemical template: almost all the compounds, based on this template, showed high levels 
of potency in the inhibition of the ROMK channels. As a further strength, some of these 
compounds, for example compounds 10C, showed diuretic effects on Sprague-Dawley rats and anti-
hypertensive activity on spontaneously hypertensive rats. However, in these early patents, the 
ROMK inhibitory activity of all the molecules was tested by means of suitable in vitro assays, but 
only very few selected compounds underwent an in vivo pharmacological evaluation of the possible 
effects on diuresis and blood pressure. Moreover, no data on the activity of these new molecular 
entities on other types of potassium channels, as for example the hERG are given in these patents 
and this knowledge could make the difference between a promising compound and a molecule with 
17 
 
dramatic adverse effects. Also pharmacokinetic data should be produced as soon as possible, in 
order to complete the profile candidates for possible clinical uses. 
In conclusion, this new class of ROMK inhibitors is still at the beginning of its history; in the 
coming years, a more detailed pharmacological profile of these new molecules will be furnished 
and will allow a different approach to diuresis based on this new exciting mechanism of action. 
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Figure 1. The role of ROMK channels in the thick ascending limb of Henle loop (TALHL) and 
cortical collecting duct (CCD) cells. Co-localization and interaction with the Na+/K+/2Cl- 
co-transporter, the Na+/K+-ATPase, the epithelial Na+ channels (ENaC), the potassium 
channels like the “Big-conductance” Ca2+-activated potassium channels (BK) and the 
“inwardly rectifying” Kir7.1, Kir2.3, Kir4.1. 
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Figure 2. Small-molecule ROMK inhibitors discovered at Vanderbilt University. 
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Figure 3. First ROMK inhibitors discovered by Merck through HTS (Compound 1) and, after 
careful examination of LC-MS, through the identification of impurity as the real ROMK 
inhibitor (Compound 2) 
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Figure 4. Compound 3,4,5,6 are ROMK inhibitors synthesized by Merck medicinal chemistry 
during SAR investigation on lead compound 2. 
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Figure 5. A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
of the renal outer medullary potassium channel. WO058134 A1; 2012. B and C are two 
examples of compounds highlighted in the patent through electrophysiological (EP) assay. 
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Figure 6. A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
of the renal outer medullary potassium channel. WO039802 A1; 2013. B and C are two 
examples of compounds highlighted in the patent through 86Rb+ efflux and Thallium (Tl+) 
assays, respectively. 
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Figure 7. A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
of the renal outer medullary potassium channel WO2013/062900 A1 and in 
WO2013/062892 A1. B and C are two examples of compounds highlighted in the patent 
WO2013/062900 A1 through Thallium (Tl+) assay while D and E are two examples of 
compounds highlighted in the patent WO2013/062892 A1 through 86Rb+ efflux and 
Thallium (Tl+) assays, respectively. 
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Figure 8. A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
of the renal outer medullary potassium channel. WO2012/058116. B and C are two 
examples of compounds highlighted in the patent through 86Rb+ efflux and Thallium (Tl+) 
assays, respectively. 
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Figure 9.A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
of the renal outer medullary potassium channel. WO2014/015495 A1 and US2014/0031349 
A1. B and C two examples of compounds highlighted in the patent through 
electrophysiological and Thallium (Tl+) assays, respectively. D is an example of compounds 
selected for the in vivo assay on SHR systolic pressure. 
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Figure 10.A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
of the renal outer medullary potassium channel. WO2010/129379 and US2014/0142115 A1. 
B is an example of compounds showing remarkable IC50 value in 86Rb+ efflux assay and C is 
a 5,5'-{piperazine-1,4-diylbis[(1R)-1-hydroxyethane-2,1-diyl]}bis(4-methyl-2-benzofuran-1 
(3H)-one), example of a compound showing appreciable values in all the biological assays 
both in vitro and in vivo. 
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Figure 11.A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
 of the renal outer medullary potassium channel. WO2014/085210 A1. The B example shows 
 appreciable values of IC50 in thallium (Tl+) and electrophysiology (EP) assays. The C 
 example shows appreciable values of IC50 in thallium (Tl+) and anti-hypertensive activity on 
 SHR in vivo. 
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Figure 12.A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
 of the renal outer medullary potassium channel. WO2013/028474 A1. The B example shows
 appreciable values of IC50 in Thallium (Th) and electrophysiology (EP) assays. The C 
 example shows and anti-hypertensive activity on SHR in vivo. Figure 12D The general 
 formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors of the renal outer 
 medullary potassium channel. WO2014/099633 A2. The 12E example shows appreciable 
 values of IC50  in Thallium (Tl+) and electrophysiology (EP) assay. 
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Figure 13.A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
 of the renal outer medullary potassium channel. WO2014/126944 A2. The B example shows
 appreciable values of IC50 in Thallium (Tl+) and electrophysiology (EP) assays. The C 
 example shows and anti-hypertensive activity on SHR in vivo. Figure 13D The general 
 formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors of the renal outer 
 medullary potassium channel. US2014/0336177 A1. The 13E example shows appreciable 
 values of IC50  in Thallium (Tl+), electrophysiology (EP) assays and anti-hypertensive 
 activity on SHR in vivo. 
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Figure 14.A The general formula reported in the patents by Merck Sharp & Dohme Corp. 
 Inhibitors of the renal outer medullary potassium channel. US2014/0309213 A1 and 
 US2014/0288042 A1. The B example shows appreciable values of IC50 in Thallium (Tl+) 
 and electrophysiology (EP) assays in the patent US2014/0309213 A1. The C example shows 
 appreciable values of IC50 in Thallium (Tl+) and electrophysiology (EP) assays in the patent 
 US2014/0288042 A1. Figure 14D The general formula reported in the patent by Merck 
 Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel. 
 US2014/0275020. The E example shows appreciable values of IC50 in Thallium (Tl+) and 
 electrophysiology (EP) assays in this patent. 
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Figure15.A The general formula reported in the patent by Merck Sharp & Dohme Corp. Inhibitors 
 of the renal outer medullary potassium channel. WO2014/150132 A1. The B and C 
 examples show appreciable values of IC50 in Thallium (Tl+) and anti-hypertensive activity 
 on SHR in vivo. Figure 15D The general formula reported in the patent by Merck Sharp & 
 Dohme Corp. Inhibitors of the renal outer medullary potassium channel. WO2015/017305 
 A1. The E and F examples show appreciable values of IC50 in Thallium (Tl+) flux assay in 
 this patent. 
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